Image

Global Von Willebrand Disease (Factor VIII Deficiency) Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Von Willebrand Disease (Factor VIII Deficiency) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Von Willebrand Disease (Factor VIII Deficiency) Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 491.00 USD Million
Diagram Market Size (Forecast Year) USD 781.99 USD Million
Diagram CAGR %

Major Markets Players

  • Novo Nordisk
  • Sun Pharmaceutical Industries
  • Zydus Cadila
  • Baxter
  • Glenmark Pharmaceuticals Limited

Global Von Willebrand Disease (Factor VIII Deficiency) Market, By Type (Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease), Drugs (Antihemophilic Factor/Von Willebrand Factor Complex, Von Willebrand Factor/Coagulation Factor VIII Complex, Von Willebrand factor (Recombinant), Desmopressin Acetate and Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Von Willebrand Disease (Factor VIII Deficiency) Market

Market Analysis and Size

In recent years, the Von Willebrand disease (factor VIII deficiency) market is anticipated to grow rapidly during the forecast period. The rise in patient support programmes is a primary driver of industry expansion. The PAN Foundation launched a new patient aid programme for persons with von Willebrand disease in July 2021. Patients who qualify for the programme will get USD 10,200 per year in financial support to cover deductibles, co-pays, and coinsurance costs related with their von Willebrand disease therapy.

Data Bridge Market Research analyses that the Von Willebrand disease (factor VIII deficiency) market was valued at USD 491 million in 2021 and is expected to reach USD 781.99 million by 2029, registering a CAGR of 5.99% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Von Willebrand Disease (Factor VIII Deficiency) is a genetic haematological bleeding illness caused by a lack of von Willebrand factors, which are faulty clotting proteins in the blood. It produces prolonged or heavy bleeding and affects both men and women equally. Frequent and prolonged nose bleeding, easy bruising, and heavy bleeding after surgery or dental work are common signs and symptoms of Von Willebrand disease.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease), Drugs (Antihemophilic Factor/Von Willebrand Factor Complex, Von Willebrand Factor/Coagulation Factor VIII Complex, Von Willebrand factor (Recombinant), Desmopressin Acetate and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Novo Nordisk A/S (Denmark), Sun Pharmaceutical Industries Ltd. (Mumbai), Zydus Cadila (Ahmedabad), Baxter (US),  Glenmark Pharmaceuticals Limited (India), Bausch Health Companies Inc. (Canada), Bayer AG (Germany), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (US), Allergan (Ireland), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Amneal Pharmaceuticals LLC. (US), Boehringer Ingelheim International GmbH. (Germany),

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies

Von Willebrand Disease (Factor VIII Deficiency) Market Dynamics

Drivers

  • Increasing prevalence of Von Willebrand disease (factor VIII deficiency)

The rising prevalence of Von Willebrand disease (factor VIII deficiency) is a primary driver of the market's growth.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Von Willebrand disease (factor VIII deficiency) market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Von Willebrand disease (factor VIII deficiency) market. Additionally, high disposable income and increase in the launch of new therapies will result in the expansion of the market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Von Willebrand disease (factor VIII deficiency) market growth.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Von Willebrand disease (factor VIII deficiency) market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of Von Willebrand disease (factor VIII deficiency) will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Von Willebrand disease (factor VIII deficiency) market. Additionally, side effects linked with the treatment and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Von Willebrand disease (factor VIII deficiency) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Von Willebrand disease (factor VIII deficiency) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Von Willebrand disease (factor VIII deficiency) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Von Willebrand Disease (Factor VIII Deficiency) Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of Von Willebrand disease (factor VIII deficiency) in recent months.

Global Von Willebrand Disease (Factor VIII Deficiency) Market Scope

The Von Willebrand disease (factor VIII deficiency) market is segmented on the basis of type, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Type 1 von Willebrand Disease
  • Type 2 von Willebrand Disease
  • Type 3 von Willebrand Disease

On the basis of type, the market is segmented into Type 1 von Willebrand Disease, Type 2 von Willebrand Disease and Type 3 von Willebrand Disease.

Drugs

  • Antihemophilic Factor/Von Willebrand Factor Complex
  • Von Willebrand Factor/Coagulation Factor VIII Complex
  • Von Willebrand factor (Recombinant)
  • Desmopressin Acetate
  • Others

Based on drugs, the market is segmented into Antihemophilic Factor/Von Willebrand Factor Complex, Von Willebrand Factor/Coagulation Factor VIII Complex, Von Willebrand factor (Recombinant), desmopressin acetate and others.

Route of Administration

The route of administration segment for the Von Willebrand disease (factor VIII deficiency) market is segmented into oral, parenteral and others.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the Von Willebrand disease (factor VIII deficiency) market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the Von Willebrand disease (factor VIII deficiency) market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Von Willebrand Disease (Factor VIII Deficiency) Market Regional Analysis/Insights

The Von Willebrand disease (factor VIII deficiency) market is analysed and market size insights and trends are provided by country, type, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Von Willebrand disease (factor VIII deficiency) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Von Willebrand disease (factor VIII deficiency) market because of the growing prevalence of Von Willebrand disease (factor VIII deficiency) in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Von Willebrand Disease (Factor VIII Deficiency) Market Share Analysis

The Von Willebrand disease (factor VIII deficiency) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Von Willebrand disease (factor VIII deficiency) market.

Some of the major players operating in the Von Willebrand disease (factor VIII deficiency) market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • AbbVie Inc. (US)
  • Cipla Inc. (US)  
  • Abbott (US)
  • Merck KGaA (Germany)
  • Amneal Pharmaceuticals LLC. (US)
  • Amgen Inc. (US)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Novo Nordisk A/S (Denmark)
  • Sun Pharmaceutical Industries Ltd. (Mumbai)
  • Zydus Cadila (Ahmedabad)
  • Baxter (US)
  • Glenmark Pharmaceuticals Limited (India)
  • Bausch Health Companies Inc. (Canada)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The market value for Von Willebrand Disease (Factor VIII Deficiency) Market is expected USD 781.99 million by 2029.
The Von Willebrand Disease (Factor VIII Deficiency) Market is to grow at a CAGR of 5.99% during the forecast by 2029
The expansion of the global Von Willebrand Disease (Factor VIII Deficiency) Market will be fueled by the changing lifestyle of people and rising prevalence of Von Willebrand disease (factor VIII deficiency). Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global Von Willebrand disease (factor VIII deficiency) market.
The major players operating in the Von Willebrand Disease (Factor VIII Deficiency) Market are Novo Nordisk A/S (Denmark), Sun Pharmaceutical Industries Ltd. (Mumbai), Zydus Cadila (Ahmedabad), Baxter (US), Glenmark Pharmaceuticals Limited (India), Bausch Health Companies Inc. (Canada), Bayer AG (Germany), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (US), Allergan (Ireland), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Amneal Pharmaceuticals LLC. (US), Boehringer Ingelheim International GmbH. (Germany).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials